PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ESTRIOL”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 181 records · Page 10Linked to original sources

Maternal pregnancy estriol levels in relation to anamnestic and fetal anthropometric data.

In epidemiologic studies of perinatal exposures, birth weight has been proposed as a proxy variable for intrauterine estrogen exposure. To assess the validity of this assumption, we performed analyses of the association between estriol levels in 188 women in the 17th, 25th, 33rd, and 37th weeks of pregnancy and the birth weights of their infants. We found a general increase in mean cumulative estriol dose with increasing birth weight category throughout pregnancy. In late pregnancy, mean pregnancy estriol level of mothers of infants in the highest birth weight category (>4,500 gm) was twice as high as that of mothers of infants in the lowest category (<2,500 gm), 775 nmol/liter and 392 nmol/liter, respectively. Smoking lowered the maternal estriol levels by 20% or more throughout pregnancy. With smoking and birth weight included in a regression analysis, maternal age, placental weight, and infant ponderal index did not add any explanatory power to the model. Our data suggest that, on an aggregate level, birth weight can be used as a proxy variable of intrauterine estriol exposure.

Birth Weight↗

Estriol enhances lipopolysaccharide-induced increases in nitric oxide production by Kupffer cells via mechanisms dependent on endotoxin.

BACKGROUND: Estriol causes sensitization of Kupffer cells to lipopolysaccharide (LPS) via mechanisms dependent on gut-derived LPS. Accordingly, this study examines the effect of estriol treatment on nitric oxide (NO) production from Kupffer cells. METHODS: Rats were given estriol (20 mg/kg body weight) intraperitoneally, and Kupffer cells were isolated 24 hr later. Some rats were treated for 4 days with 150 mg/kg/day of polymyxin B and 450 mg/kg/day of neomycin to prevent growth of intestinal bacteria, the primary source of endotoxin in the gastrointestinal tract. After addition of LPS, NO production by Kupffer cell was detected using a fluorescence indicator, DAF-2. RESULTS: Twenty-four hours after estriol administration, LPS-induced NO production by Kupffer cells was enhanced as compared with control Kupffer cells. Sterilization of the gut with antibiotics blocked this enhancement. CONCLUSIONS: Estriol treatment in vivo enhances LPS-induced NO production in Kupffer cells.

Animals↗

Urethral sphincteric insufficiency in postmenopausal females: treatment with phenylpropanolamine and estriol separately and in combination. A urodynamic and clinical evaluation.

A randomized open comparative cross-over trial was carried out in 20 postmenopausal women, mean age 69 years, suffering from urinary incontinence due to urethral sphincteric insufficiency. They were treated with phenylpropanolamine (PPA) 50 mg p.o. twice daily or estriol vaginal suppositories 1 mg daily separately and in combination for periods of 4 weeks. Urodynamic investigations were carried out before and after each period of treatment. Both PPA and estriol increased the maximal urethral closure pressure and the continence area significantly compared to the initial values, but combined treatment was substantially more effective. The functional urethral length increased significantly while on estriol. No significant change was registered in the bladder pressure or in the pressure transmission ratio. PPA was clinically more effective than estriol, but not sufficient to obtain complete continence. With combined treatment 8 patients became completely continent, 9 were considerably improved and only 1 patient remained unchanged. 2 patients dropped out of the study because of side effects. Combined treatment with PPA and estriol represents a recommendable treatment to postmenopausal women with urinary incontinence due to urethral sphincteric insufficiency.

Aged↗

Serum unconjugated estriol in the menstrual cycle and early pregnancy.

A radioimmunoassay for serum unconjugated estriol in the menstrual cycle with a sensitivity of about 5 pg/ml is described. 8 cycles were studied. In 2 cycles, single spikes of 22 and 30 pg/ml were obtained. In 3 cycles, concentrations of 4-5 pg/ml were found whereas in the other 3 studies, no estriol was detected. In general, peaks of estriol corresponded to peaks in estradiol plus estrone. Patients in 4-12 weeks of gestation were also studied. Concentrations as high as 262 pg/ml were found but in isolated instances, no estriol was detected. The results support the view that in contrast to the pregnant state, in the normal menstrual cycle, the bulk of the estriol produced is conjugated before release into the blood.

Estriol↗

Identification and measurement of urinary estrone, estradiol-17 beta, estriol, pregnanediol and androsterone during the menstrual cycle of the orangutan.

Urinary estrone, estradiol-17beta, estriol, pregnanediol and androsterone were identified and measured during 3 menstrual cycles in 2 female orangutans. In 2 of the cycles, the animals excreted 1-8 mug/day estrone, 0.5-6 mug/day estradiol-17beta, 1-8 mug/day estriol, 20-206 mug/day pregnanediol and 120-522 mug/day androsterone during the first half of the menstrual cycle. In the second half of the cycle, corresponding values were 3-21 mug/day estrone, 2-10 mug/day estradiol-17beta, 1-9 mug/day estriol, 54-800 mug/day pregnanediol and 90-1158 mug/day androsterone. In 1 cycle, the estrogen values for the second half were considerably higher, possibly due to the animal becoming pregnant just before this study commenced. The values for estrone and estradiol-17beta are similar to those found in the human and chimpanzee menstrual cycle. The values for estriol were lower than in the human but higher than in the chimpanzee. Levels for urinary pregnanediol and androsterone were significantly lower than in the human. Variations during the menstrual cycle for estrone were characterized by a midcycle peak followed by a second peak in the luteal phase. No definite pattern was apparent for estradiol-17beta or estriol. Both urinary pregnanediol and androsterone levels were low during the first half of the cycle, started to rise just after midcycle, and showed a peak during the second half of the menstrual cycle.

Androsterone↗

Congenital hypopituitarism as a cause of undetectable estriol levels in the maternal triple-marker screen.

We are reporting a child with congenital panhypopituitarism, in whom deficient fetal steroidogenesis was suspected prenatally because of undetectable estriol levels measured in the maternal triple-marker screen. No fetal abnormalities were detected by ultrasonography. Amniocentesis demonstrated a normal 46,XX karyotype. Measurement of maternal urinary steroids failed to show elevation in the excretion of the major precursor for estriol, 16 alpha-hydroxydehydroepiandrosterone, indicating that the fetus did not have steroid sulfatase deficiency (placental sulfatase deficiency), the most common genetic cause of extremely low estriol. The steroid analysis excluded other rare single gene defects, including aromatase deficiency and 17 alpha-hydroxylase deficiency. We therefore suspected that the cause of low estriol in this fetus was adrenal insufficiency. Postnatal evaluation was consistent with panhypopituitarism, characterized by deficiency of all anterior pituitary hormones. Because this screen is now offered to more than half the pregnant women in the United States, reports of low estriol levels have become increasingly common. Therefore, it is essential that physicians be familiar with the various etiologies, perform the appropriate antenatal evaluation to determine the specific cause, and closely monitor both mother and child ante- and postnatally.

Adrenal Gland Diseases↗

[A rapid and direct 125 I-based radioimmunoassay for unconjugated estriol in pregnancy serum and its clinical application (author's transl)].

A rapid and simple R.I.A. method for serum unconjugated estriol in pregnancy had been studied for its usefulness as a routine obstetrical test to assess fetal well-being. Diluted serum samples or known amounts of standard estriol were applied with 125 I-estriol on pre-packed minicolumns of Sephadex G-25, followed by appropriately diluted antiserum. During incubation, the columns were counted in an Auto Well gamma-System to read the total counts (T). After a 90 minute incubation period, the columns were eluted with a buffer solution to remove the bound fraction, and the free estriol remaining in the columns was counted (F). Two quality control samples and sera from 74 pregnant women were analysed by this new method, and the results were compared to those obtained by the conventional radioimmunoassay method. The new column method is simple, specific and accurate. Results can be calculated within 4 hours after 30 sample sera are brought into the laboratory. Within and between assay coefficients, variations are 12.6 and 13.5%, respectively. This method correlates well with the results of the conventional method (r=0.7088, p less than 0.001), which requires almost 2 full days to process the same numbers of samples. Results of clinical cases as well as advantages of measuring free-circulating estriol in pregnancy are discussed.

Anencephaly↗

The precision of clinical estriol and total estrogen estimations in pregnancy urine.

1. A study of the precision of clinical estriol- and total estrogen determinations in late pregnancy urine was carried out in collaboration with 26 clinical laboratories in the Netherlands and one laboratory in Suriname. 2. Ten urine samples were circulated twice with an interval of 2 weeks. 3. It was shown, that repeated analysis of the same sample in the same clinical laboratory in different assays can yield differences in results up to 40%. This interassay variation can be regarded as the main source of uncertainty of results of clinical estriol and total estrogen determinations. 4. The quantitative differences between results of total estrogen methods and a gas chromatographic method, which measures only estriol, were shown to be caused primarily by the lower recovery of the glucuronide of estriol (both native and added) in the latter method. 5. As expected, methods based on the principle of Ittrich (1960), Acta Endocrinol. 35, 34-48) proved to be more susceptible to the disturbing influence of glucose than a gas chromatographic method that measured estriol specifically. 6. Various recommendations to improve the precision of clinical estrogen determinations in pregnancy urine resulted from this study.

Estriol↗

Low estriol levels in the maternal triple-marker screen as a predictor of isolated adrenocorticotropic hormone deficiency caused by a new mutation in the TPIT gene.

Isolated adrenocorticotropic hormone (ACTH) deficiency (IAD) is a rare cause of adrenocortical insufficiency, especially in children, and may be an underestimated cause of neonatal death. Early postnatal diagnosis may prevent hypoglycemic seizures, Addisonian crises, and death. There are also occasional reports of prenatal diagnosis of IAD by findings on the maternal triple-marker screen (TMST), a combined serum analyte test that measures levels of alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol for the detection of Down syndrome and open neural-tube defects. An isolated low estriol level is usually correlated with compromised uteroplacental perfusion and frequently associated with fetal death. A low estriol level in the context of normal fetal sonography and growth, after exclusion of placental sulfatase deficiency and Smith-Lemli-Opitz syndrome, should raise the suspicion of deficient fetal steroidogenesis, which leads to decreased production of adrenal dehydroepiandrosterone sulfate. We describe 2 brothers with adrenal insufficiency resulting from IAD. The parents are first cousins whose first son is healthy. During the pregnancy of the second son, who died at the age of 7 weeks as a result of presumed cardiomyopathy, a low estriol level on the TMST was ignored because of a normal fetal ultrasound. In the third pregnancy, a low level was found again, and the mother was referred to our tertiary center. Ultrasonography revealed no abnormalities, and karyotype was normal. Normal levels of steroid sulfatase activity and 7-dehydrocholesterol ruled out X-linked ichthyosis and Smith-Lemli-Opitz syndrome, respectively. Postnatally, basal and stimulated cortisol and ACTH levels were low. Other pituitary functions were normal, suggesting the diagnosis of IAD. The patient was treated with a stress dose of hydrocortisone on day 2 of life, which was tapered to a maintenance dose. At the time of this writing, he was 7 months old, with normal growth and development. Recently, loss-of-function mutations in the human TPIT gene were detected in autosomal recessive IAD. TPIT is a cell-restricted T-box transcription factor that is important for the terminal differentiation of pituitary corticotrophs. Therefore, we performed molecular analysis of the TPIT gene, which revealed a new mutation (IVS4+1G>A) that affects the first nucleotide of the splice site at the 5' end of the fourth intron. This stop codon probably leads to loss of TPIT function by nonsense-mediated mRNA decay, as it does for other TPIT nonsense mutations. We recommend that pregnant women with an isolated low estriol level of unexplained etiology be referred for additional evaluation by a multidisciplinary team that includes a geneticist and pediatric endocrinologist. Prompt ACTH testing in the first postnatal days will allow for early diagnosis. The immediate institution of glucocorticoid therapy, with proper instructions for stress management, can prevent unnecessary neonatal death secondary to an easily treatable disease.

Adrenal Insufficiency↗

Estriol concentrations in urine and serum in patients with various intestinal diseases.

Pregnant women with ulcerative colitis shows frequently low estriol values in both serum and urine. 18 patients with ulcerative colitis, 4 patien;s with mb. Crohn, and 3 patients with a by-pass operation were examined. Low estriol concentrations were seen only in the patients with ulcerative colitis especially in patients, where an operation has been performed. In one patient with severe diarrhea the estriol concentration in serum was low until the intestinal function normalised and the estriol concentration went up exactly when the diarrhea stopped. However, no unequivocal connection between low estriol concentrations and diarrhea could be demonstrated.

Colitis, Ulcerative↗

Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women.

In a comparative randomized cross-over study the absorption of a single dose of 0.5 mg estriol from a vaginal cream or a vaginal suppository (OvestinR, Organon, The Netherlands) was studied. Eight healthy postmenopausal women participated and the preparations were given with an interval of 14 days. Blood sampling was performed twice before application and then after 1/4, 1/2, 1, 2, 4, 6, 8, 24 and 48 hours. Serum was analysed for unconjugated and conjugated estriol (E3), FSH and LH by radio-immunoassay. Considerable interindividual variations in serum levels of unconjugated E3 were found but mean values were about equal throughout the study for the two preparations. Peak levels of 0.5-0.6 nmol/l were achieved 1-2 hours after application of the preparations and after 24 hours no unconjugated E3 was measurable. Conjugated E3 rose rapidly but within 48 hours serum concentrations reached baseline levels. A maximum decrease in serum LH levels of about 40% was obtained with both preparations after 6 hours and the return to baseline within 24 hours indicates a relationship to unconjugated E3. FSH in serum was maximally suppressed 6-12%. Estriol is thus readily absorbed by the vaginal route and peak levels of unconjugated E3 after insertion of 0.5 mg estriol seem to be comparable to those obtained after 8-12 mg estriol given orally.

Absorption↗

Scanning electron microscopy of the responses of postmenopausal endometrium to treatment with estriol and estriolprogesterone.

Seven postmenopausal women are given estriol orally in a daily dose of 1 mg x 2 or 5 mg x 2 for 14 or 28 days and 2 women were sequentially treated with 5 mg x 2 of estriol orally for 21 days, with the addition of 0.2 g x 2 of progesterone rectally in the last 7 days. Three women served as controls. Scanning electron microscopy revealed that the former treatment with estriol was sufficient to produce an estrogen response in the non-ciliated uterine epithelial cells, which developed many long microvilli, sometimes arranged in tufts. The sequential treatment with initial estriol priming followed by estriol and progesterone combined resulted in a slight secretory transformation of the uterine epithelium, observed as an increase in size and number of the apical protrusions of the cells.

Aged↗

Diurnal variations in unconjugated plasma and total urinary estriol levels in late normal pregnancy.

Diurnal variations in plasma unconjugated estriol and urinary estriol were assessed in 12 pregnant women during the 3rd trimester of uncomplicated pregnancies. Commercially available 125I-labelled radioimmunoassay kits were used. The preliminary data presented here support the hypothesis that there is no circadian rhythm of unconjugated plasma estriol in normal late pregnancy. Total urinary estriol reaches a nadir during the sleep hours (24.00-6.00). A biological carrier 'stick' for estriol measurements might serve as test of choice in the monitoring of high-risk pregnancy as well as for identifying pregnancies complicated by chromosomal abnormalities (e.g., Down's syndrome).

Adult↗

Receptor and biological response to estriol in the fetal uterus of guinea pig.

The binding of 3H-estriol was examined in the fetal uterus of guinea pig. The physico-chemical characteristics of the binding of 3H-estriol to macromolecules are similar to the typical receptor protein for estrogens. Different estrogens (estriol, estradiol, estrone and diethylstilbestrol) compete with this binding but progesterone and testosterone have no effect. The binding affinity has a Kd of 5.5 +/- 1.6 +/- 10(-10) M. By ultracentrifugation in sucrose gradient, two specific components with sedimentation coefficients of 8 and 4S are found. Competition studies suggest that the same specific binding sites may be present for estriol (E3) and for estradiol. The s.c. administration of E3 to the pregnant guinea pig (1 mg/day per kg body weight for 3 days) provokes two biological responses in the fetal uterus: a uterothopic effect and a significant increase in the progesterone receptor. The increase in the fetal uterine weight is 50-70% in relation to the non-treated animals and the progesterone receptor concentration is 10-14 times higher than in the control animals. These effects are similar (or slightly higher) than in animals primed with equimolecular quantities of estradiol. In contrast, single daily injections of E3 to newborn guinea pig, results only in weak uterotrophic activity. It is concluded that estriol is capable of causing a biological response in the uterus during intra-uterine life.

Animals↗

Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.

The protective effect of pregnancy on putative Th1-mediated autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, is associated with a Th1 to Th2 immune shift during pregnancy. The hormone estriol increases during pregnancy and has been shown to ameliorate experimental autoimmune encephalomyelitis and collagen-induced arthritis. In addition, estrogens induce cytokine changes consistent with a Th1 to Th2 shift when administered in vitro to human immune cells and in vivo to mice. In a pilot trial, oral estriol treatment of relapsing remitting multiple sclerosis patients caused significant decreases in enhancing lesions on brain magnetic resonance imaging. Here, the immunomodulatory effects of oral estriol therapy were assessed. PBMCs collected longitudinally during the trial were stimulated with mitogens, recall Ags, and glatiramer acetate. Cytokine profiles of stimulated PBMCs were determined by intracellular cytokine staining (IL-5, IL-10, IL-12 p40, TNF-alpha, and IFN-gamma) and cytometric bead array (IL-2, IL-4, IL-5, IL-10, TNF-alpha, and IFN-gamma). Significantly increased levels of IL-5 and IL-10 and decreased TNF-alpha were observed in stimulated PBMC isolated during estriol treatment. These changes in cytokines correlated with reductions of enhancing lesions on magnetic resonance imaging in relapsing remitting multiple sclerosis. The increase in IL-5 was primarily due to an increase in CD4(+) and CD8(+) T cells, the increase in IL-10 was primarily due to an increase in CD64(+) monocytes/macrophages with some effect in T cells, while the decrease in TNF-alpha was primarily due to a decrease in CD8(+) T cells. Further study of oral estriol therapy is warranted in Th1-mediated autoimmune diseases with known improvement during pregnancy.

Adjuvants, Immunologic↗

[Excretion of estriol-3-sulfate in the urine of pregnant women during the last trimester of pregnancy].

In this publication a method is given for quantitative determination of estriol-3-sulfate in urine of pregnant women. After separation of estriol-3-sulfate from glucuronides by liquid partition using acetone and NaOH the sulfate is hydrolyzed to estriol. The estriol is converted to an azodye which is separated by TLC and measured by remission analysis which a chromatogramm spectrophotometer. 59 cases have been investigated and the excretion pattern is given for estriol-3-sulfate in the 3rd trimester of pregnancy. The average excretion is 100 mug/24 hours in the 28th week and 356 mug/24 hours in the 42nd week of pregnancy.

Adult↗

Identification of 16 alpha-hydroxy-estrone as a metabolite of estriol.

During a study on the uptake and retention of estrogens by uterine tissues in postmenopausal women, evidence was obtained of the presence of a metabolite of estriol, tentatively identified as 16 alpha-hydroxy-estrone (16-OHE1). In view of the recent hypothesis concerning the role of 16-OHE1 as a risk marker for breast cancer, attempts were made to establish the identity of the metabolite. After infusions with labelled estriol, radioactive material with chromatographic properties of 16-OHE1 was observed; insufficient material was obtained for micro-recrystallization. After oral administration of estriol, myometrial tissue was extracted, then purified by chromatography and the appropriate fraction was analyzed by gas chromatography-mass spectrometry, monitored at 3 specific mass units. In the women receiving estriol the presence of 16-OHE1 could be unequivocally demonstrated, the concentrations in the myometrium being 6 and 18 ng/g tissue, whereas less than 0.2 ng/g was found in an untreated patient. This identification of 16-OHE1 does not support the hypothesis about its prominent role in human breast cancer. Additional investigations will be necessary to clarify its role in the process of stimulation of estrogen-sensitive tissues under physiological conditions and after exogenous administration of estriol.

Biotransformation↗

Diurnal variations in unconjugated and total plasma estriol levels in late normal pregnancy.

Diurnal variations in plasma unconjugated and total estriol were assessed in 11 third-trimester subjects with uncomplicated pregnancies. Commercially available 125I-labeled radioimmunoassay kits were used. Total plasma estriols reach a nadir during the hours of sleep (400 and 700 hours) which exceeds the episodic fluctuations seen from day to day or during a given 90-minute period. Plasma unconjugated estriol fluctuations over 24 hours did not significantly exceed our previously reported episodic fluctuation of 15.6 +/- 8.2%. The data are interpreted as showing no circadian rhythm, but reflecting, in the case of total plasma estriols, an effect of improved renal clearance during hours of rest. Plasma unconjugated estriol emerges as the test of choice in the monitoring of high-risk pregnancies.

Adult↗